HYDROCHLOROTHIAZIDE TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
24-05-2022
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
HYDROCHLOROTHIAZIDE
Tilgængelig fra:
PRO DOC LIMITEE
ATC-kode:
C03AA03
INN (International Name):
HYDROCHLOROTHIAZIDE
Dosering:
50MG
Lægemiddelform:
TABLET
Sammensætning:
HYDROCHLOROTHIAZIDE 50MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100
Recept type:
Prescription
Terapeutisk område:
THIAZIDE DIURETICS
Produkt oversigt:
Active ingredient group (AIG) number: 0101048001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2019-04-01
Produktets egenskaber
HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
PRODUCT MONOGRAPH
PR
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide Tablets USP
25 mg and 50 mg
DIURETIC - ANTIHYPERTENSIVE
Pro Doc Ltée
2925 Boul Industriel
Laval, Quebec
H7L 3W9
www.prodoc.qc.ca
Submission Control No: 263745
Date of Revision:
May 24, 2022
HYDROCHLOROTHIAZIDE Product Monograph Page 1 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
2
SUMMARY
PRODUCT
INFORMATION
..............................................................................................
2
INDICATIONS
AND
CLINICAL
USE
....................................................................................................
2
CONTRAINDICATIONS
.........................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................
3
ADVERSE
REACTIONS
.........................................................................................................................
7
DRUG
INTERACTIONS
..........................................................................................................................
7
DOSAGE
AND
ADMINISTRATION
....................................................................................................
11
OVERDOSAGE
......................................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
..................................................................................
12
STORAGE
AND
STABILITY
................................................................................................................
13
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
....................................................................
13
PART II: SCIENTIFIC INFORMATION
..................................................................
Læs hele dokumentet
